The Gross Margin of Veracyte, Inc. (VCYT) is
70.10%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
70.10%
|
| 2024-12-31 |
66.88%
|
| 2023-12-31 |
68.73%
|
| 2022-12-31 |
65.73%
|
| 2021-12-31 |
66.10%
|
| 2020-12-31 |
64.68%
|
| 2019-12-31 |
69.68%
|
| 2018-12-31 |
64.02%
|
| 2017-12-31 |
60.83%
|
| 2016-12-31 |
60.83%
|
| Ticker |
Name |
Value |
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
LEGN
|
Legend Biotech Corporation
|
60.34%
|
|
OPGN
|
CapForce Inc
|
99.36%
|
|
GNLKQ
|
Genelink Inc
|
21.75%
|
|
IMCR
|
Immunocore Holdings PLC
|
98.73%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
ALXO
|
ALX Oncology Holdings Inc
|
9.32%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
ARNA
|
Arena Pharmaceuticals Inc
|
78.92%
|
|
BHVN
|
Biohaven Ltd.
|
72.18%
|
|
FOLD
|
Amicus Therapeutics Inc
|
88.50%
|
|
IGMS
|
IGM Biosciences LLC
|
7775.20%
|
|
RVMD
|
Revolution Medicines, Inc.
|
7775.20%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
89.81%
|
|
CDNA
|
CareDx, Inc.
|
67.55%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
93.45%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
EDIT
|
Editas Medicine, Inc.
|
7775.20%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
7775.20%
|
|
CCXI
|
Churchill Capital Corp XI
|
99.06%
|
|
RLAY
|
Relay Therapeutics, Inc.
|
7775.20%
|
|
SRNE
|
Sorrento Therapeutics Inc
|
46.82%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
AGIO
|
Agios Pharmaceuticals, Inc.
|
88.26%
|
|
FGEN
|
FibroGen Inc
|
47.47%
|
|
GBT
|
Global Blood Therapeutics Inc
|
98.30%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
LGND
|
Ligand Pharmaceuticals Incorporated
|
74.78%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
GTH
|
Genetron Holdings Ltd
|
43.25%
|
|
INSM
|
Insmed Incorporated
|
79.73%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
34.28%
|
|
VIE
|
Viela Bio Inc
|
82.49%
|